Mm1 s

Manufactured by Leibniz Institute DSMZ

Sourced in Germany

The MM1.S is a laboratory equipment produced by the Leibniz Institute DSMZ. It serves as a micromanipulator, a device used for the precise manipulation of small objects, such as cells or microorganisms, under a microscope.

Automatically generated - may contain errors

Lab products found in correlation

7 protocols using mm1 s

Characterization of Multiple Myeloma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

AMO-1 was kindly provided by Dr C. Driessen (University of Tubingen, Germany). LP1, MM1.S, OPM2, and NCI-H929 were purchased from DSMZ, which certified authentication performed by short tandem repeat DNA typing. All HMCL were immediately frozen and used from the original stock within 6 months. HMCL were cultured in RPMI-1640 medium (Gibco^®, Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin (Gibco^®) at 37°C in 5% CO₂ atmosphere, and routinely tested to rule out mycoplasma contamination.

Taiana E., Bandini C., Favasuli V.K., Ronchetti D., Silvestris I., Puccio N., Todoerti K., Erratico S., Giannandrea D., Bolli N., Amodio N., Ciarrocchi A., Chiaramonte R., Torrente Y., Piva R, & Neri A. (2022). Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins. Haematologica, 108(1), 219-233.

+ Open protocol

+ Expand

Establishing Myeloma Cell Line Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols

MM cell lines NCI-H929, MM.1S, and JJN-3 were purchased from DSMZ, while AMO-1 and AMO-BZB cells were kindly provided by Dr. C. Driessen (University of Tubingen, Tubingen, Germany). All cellular models have been tested for mycoplasma before use. Whole peripheral blood was obtained from healthy blood donors who provided informed consent according to our institutional bioethical requirement. Peripheral blood mononuclear cells (PBMCs) were isolated from each buffy coat by density gradient centrifugation using Lympholyte Cell Separation Media (Euroclone, Milan, Italy). The culture media was RPMI-1640 supplemented with 10% FBS, 2 μmol/L glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (GIBCO; Thermo Fisher Scientific, Waltham, MA, USA).

Grillone K., Riillo C., Rocca R., Ascrizzi S., Spanò V., Scionti F., Polerà N., Maruca A., Barreca M., Juli G., Arbitrio M., Di Martino M.T., Caracciolo D., Tagliaferri P., Alcaro S., Montalbano A., Barraja P, & Tassone P. (2022). The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma. International Journal of Molecular Sciences, 23(18), 10222.

+ Open protocol

+ Expand

Culturing and Sourcing Multiple Myeloma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell lines L363, OPM-2, MM1.S, RPMI-8226, and SU-DHL-2 were cultured in RPMI 1640 GlutaMAX HEPES culture medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Biowest) and 100 µg/ml penicillin–streptomycin (Gibco/Life Technologies). UM9 was cultured with 20% FBS, and NCI-H929 with 20% FBS, 1 mM sodium pyruvate (Thermo Fisher), and 50 µM β-mercaptoethanol (Life Technologies). OCI-Ly1, OCI-Ly3, OCI-Ly7, and OCI-Ly10 were cultured in Iscove’s modified Dulbecco’s medium (Life Technologies) supplemented with 20% FBS and 100 µg/ml penicillin–streptomycin. Cell lines L363, RPMI-8226, OPM-2, OCI-Ly3, OCI-Ly7, OCI-Ly1 and NCI-H929 were purchased from DSMZ, MM1.S, OCI-Ly10, and SU-DHL-2 were purchased from ATCC. Cell line UM9 was derived from an MM patient at our UMCU hospital). All cell lines were tested negative for mycoplasma before and during the experiments. Primary MM cell samples were derived from patients diagnosed at the Academic Medical Center, Amsterdam, The Netherlands. This study was conducted and approved by the AMC Medical Committee on Human Experimentation. Informed consent was obtained in accordance with the Declaration of Helsinki.

Slomp A., Moesbergen L.M., Eldering E., Kersten M.J., Minnema M.C, & Peperzak V. (2021). Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. Cell Death & Disease, 12(3), 229.

+ Open protocol

+ Expand

Investigating Multiple Myeloma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

MM cell lines RPMI8226 and MM.1S were purchased from DSMZ(Braunschweig, Germany), and CAG and ARP1 were generously provided Dr. Qing Yi (Center for Hematologic Malignancy, Research Institute, Houston, TX, USA). All the cell lines were maintained in RPMI-1640 medium (Corning Cellgro, USA) supplemented with 10% fetal bovine serum (FBS) (GIBCO, CA, USA), 100U/ml penicillin and 100μg/ml streptomycin at 37°C and 5% CO₂ in air. BM samples from MM patients and peripheral blood mononuclear cells (PBMCs) from healthy donors were obtained after informed consent was provided following approval by the Ethics Committee of Affiliated Hospital of Weifang Medical University. MG132 and Cycloheximide were purchased from Sigma-Aldrich. Primary antibodies against KDM2A, PFKFB3, CDK6, MCL-1 and ubiquitin were purchased from Abcam (Cambridge, UK). Anti-VEGF antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). GAPDH and Bax were purchased from Cell Signaling Technology (Danvers, USA). HA was obtained from Roche (Basel, Switzerland). Horseradish peroxidase (HRP)-conjugated anti-rabbit antibodies were obtained from Jackson ImmunoResearch Laboratories (Lancaster, USA). Lipofectamine 2000 reagent (Invitrogen) was used for transient transfection. The shRNA or siRNA sequences used were shown in Supplementary Table S1.

Liu X., Li J., Wang Z., Meng J., Wang A., Zhao X., Xu Q., Cai Z, & Hu Z. (2021). KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells. Frontiers in Oncology, 11, 653788.

+ Open protocol

+ Expand

Cell Culture Conditions for HEK293T, HeLa, and Multiple Myeloma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

HEK293T (ATCC: CRL-3216), CRBN^−/− HEK293FT (kindly provided by WG Kaelin) and HeLa (ATCC: CCL-2) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The human multiple myeloma cell lines MM1.S (ATCC: CRL-2974), MM1.S CRBN^−/− (independent clones T11 and T21; both kind gifts of WG Kaelin), U266 (DSMZ: ACC-9), KMS 12BM (DSMZ: ACC-551), RPMI 8226 (DSMZ: ACC-402), JJN3 (DSMZ: ACC-541) were cultured in RPMI-1640 (GIBCO) with 10% heat-inactivated FBS and 1% penicillin-streptomycin. All cells tested mycoplasma negative by a PCR detection method.

Heider M., Eichner R., Stroh J., Morath V., Kuisl A., Zecha J., Lawatscheck J., Baek K., Garz A.K., Rudelius M., Deuschle F.C., Keller U., Lemeer S., Verbeek M., Götze K.S., Skerra A., Weber W.A., Buchner J., Schulman B.A., Kuster B., Fernández-Sáiz V, & Bassermann F. (2021). The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Molecular Cell, 81(6), 1170-1186.e10.

+ Open protocol

+ Expand

Cell Line Characterization for MM Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

The cell lines used in this study were HMCLs MM.1S, KMS27, KMS28BM, KMS26, OPM2, and KMS11 and human bone osteosarcoma U2OS. MM.1S was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). The U2OS cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). KMS27 and KMS28BM were provided by Dr. Hideto Tamura (Nippon Medical School, Tokyo, Japan). The KMS26 and KMS11 cells were provided by Dr. Takemi Otsuki (Kawasaki Medical School, Okayama, Japan). OPM2 was provided by Dr. Masaki Ri (Nagoya City University, Aichi, Japan). Human MCLs were cultured in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO, USA), while U2OS cells were cultured in Eagle’s medium (DMEM; FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) supplemented with 10% fetal bovine serum at 37 °C in 5% CO₂.

Murakami Y., Kimura-Masuda K., Oda T., Matsumura I., Masuda Y., Ishihara R., Watanabe S., Kuroda Y., Kasamatsu T., Gotoh N., Takei H., Kobayashi N., Saitoh T., Murakami H, & Handa H. (2022). MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression. Genes, 14(1), 100.

+ Open protocol

+ Expand

Provenance Verification of Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary CLL cell lines (n=46) and age-matched normal B and T cells were obtained with informed consent in accordance with the ethical approval granted by South East Wales Research Ethics Committee (02/4806). In addition, five multiple myeloma cell lines, JJN3, U266, OPM2, MM.1S and H929, were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen. The provenance of the cell lines was verified by multiplex polymerase chain reaction of minisatellite markers; all were certified mycoplasma-free.

Lewis T., Corcoran D.B., Thurston D.E., Giles P.J., Ashelford K., Walsby E.J., Fegan C.D., Pepper A.G., Rahman K.M, & Pepper C. (2020). Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit nuclear factor-κB activity and synergize with bortezomib and ibrutinib in hematologic cancers. Haematologica, 106(4), 958-967.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!